The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Evolving strategies for using BTK inhibitors in CLL
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, discusses evolving strategies using Bruton’s tyrosine kinase (BTK) inhibitors to treat chronic lymphocytic leukemia (CLL), commenting on the development of second-generation and third-generation BTK inhibitors which aim to achieve an improved safety and tolerability profile, in particular in regards to cardiovascular toxicities. Dr Ghia also talks on the development of pirtobrutinib, a third-generation non-covalent BTK inhibitor, highlighting the benefits of it being reversible and describing how this impacts drug sequencing. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
